cis-Dichlorodiamminepltinum(II) in adult patients: Southwest Oncology Group Studies.
In addition to cis-dichlorodiammineplatinum(II) studies in lymphomas and testicular cancer and a broader phase II study of all genitourinary malignancies, the Southwest Oncology Group is currently conducting eight other studies which examine the effectiveness of this drug in adult patients with a variety of tumor types. This report will give preliminary analyses of the five studies for which there are early data, plus briefly describe the design of the three remaining protocols for which there are no data as yet.
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002945:Cisplatin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy
D000970:Antineoplastic Agents; D002945:Cisplatin